Menu
Menu
SOPHiA GENETICS is excited to attend this year’s Association of Molecular Pathology (AMP) Annual Meeting!
Find us at booth #921 to learn about how we are enabling breakthrough innovations in cancer research.
Wednesday, November 12, 10:00 – 10:50 am | Corporate Workshops | 160C Level 1
Elevating CGP with Agile Solutions: The New MSK-IMPACT® Flex powered with SOPHiA DDM™
Speakers:
Wednesday, November 12, 11:00 – 11:50 am | Corporate Workshops | 160C Level 1
Redefining Precision Oncology with MSK-ACCESS® powered with SOPHiA DDM™
Speakers:
Friday, November 14, 9:15am – 10:15am | Poster number: ST044
Robust RNA profiling using the SOPHiA DDM™ RNAtarget Oncology Solution with FFPE tumor samples
Authored by: Izabela Matyszczak, Slawomir Kubik, Jonathan Bieler, Ewan Smith, Jonathan Lopez, Alexandre Harlé, Christian Pozzorini, Zhenyu Xu
Saturday, November 15, 9:15am – 10:15am | Poster number: ST041
MSK-IMPACT Flex powered with SOPHiA DDM™ enables sample-specific comprehensive genomic profiling through selective analysis of DNA and RNA biomarkers
Authored by: Izabela Matyszczak, Christian Pozzorini, Gregoire André, Tommaso Coletta, Amjad Alkodsi, Frederic Michaud, Yvan Wenger, Elia Magrinelli, Anjali Anjali, Zhenyu Xu
We are thrilled to be back at 15th World Clinical Biomarkers & Companion Diagnostics Summit. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
If you are attending, don’t miss:
Lunch & Learn hosted by SOPHiA GENETICS on Wednesday, September 24th, from 1.10 to 2.10 pm.
Join us for a special lunch session spotlighting the journey of MSK-ACCESS® powered with SOPHiA DDM™ from an in-house solution at Memorial Sloan Kettering Cancer Center (MSK) to a globally scalable, decentralized, best-in-class liquid biopsy platform, through a strategic collaboration with SOPHiA GENETICS.
Talk on Thursday, September 25th, from 11.00 to 11.30 am, in Track A.
“Bridging the Gap: A Hybrid Deployment Model for Scaling Innovation in Oncology”
Jess Lambe, Vice President and Managing Director of BioPharma Business Development, SOPHiA GENETICS
Join us at ESMO Asia 2025! Learn how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform by leveraging our unique AI-powered expertise and comprehensive product offering. Discover how we uncover insights from complex oncology data, driving faster discovery of new stratifying biomarkers, in addition to aiding in the commercialization of precision medicines.
We are excited to announce our presence at the World Companion Diagnostics & Liquid Biopsy Summit APAC. Meet our BioPharma team to learn more about our liquid biopsy portfolio and how it supports BioPharma companies to address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
If you are around, don’t miss our Plenary talk, to discover how SOPHiA GENETICS is empowering Pharma companies to advance precision medicine with next-generation genomics solutions, enhancing worldwide patient access to innovative therapies
“Innovative Ways to Democratize Precision Medicine Testing”
Nicholas Tan, Managing Director APAC, SOPHiA GENETICS
If you are around, don't miss our Plenary talk, on November 12th from 12.00 to 12.30 pm, to discover how SOPHiA GENETICS is empowering Pharma companies to advance precision medicine with next-generation genomics solutions, enhancing worldwide patient access to innovative therapies.
We are glad to return to BioTechX Europe in Basel. Meet our BioPharma team and learn how we help BioPharma companies address challenges throughout the drug development continuum with diagnostics and data solutions tailored to their needs, bringing more effective drugs to the right patients.
If you are attending, join us on October 6th at 14:50, in the Big Data in Oncology track, for an engaging talk about how SOPHiA GENETICS is building a world where clinicians make faster, more informed decisions, and every patient contributes to a smarter and more equitable future in medicine
“Unlocking the Power of Data: AI-Driven Insights for Precision Medicine”
Guillaume Cettou, Global Head of Data Partnerships, SOPHiA GENETICS
You’ll get to explore howAI and collective intelligence are translating vast amounts of data into actionable insights, enabling clinicians to make more informed decisions and improving outcomes across borders.
We are glad to be at BioTechX USA 2025, where you will have the chance to meet our BioPharma team for two days of exciting networking, innovation, and insights sharing on the potential of AI-driven solutions to transform precision medicine.
If you are around, don’t miss our talk on September 17th from 12.05 to 12.25 PM, in the AI in Drug Development and Discovery track, for an insightful talk about how SOPHiA GENETICS is building a world where clinicians make faster, more informed decisions, and every patient contributes to a smarter and more equitable future in medicine.
“Unlocking the Power of Data: AI-Driven Insights for Precision Medicine”
Kellen Sanger, Head of Strategy and Programs, SOPHiA GENETICS
You’ll get to explore howAI and collective intelligence are translating vast amounts of data into actionable insights, enabling clinicians to make more informed decisions and improving outcomes across borders.
We are glad to return to Swiss Biotech Day 2025, where you will have the chance to meet our BioPharma and Medical teams for two days of exciting networking, innovation, and insights sharing on the potential of AI-driven solutions to transform precision medicine.
Join us on May 5th at 16:45 pm, in the Montreal room, for an engaging panel discussion on the transformative role of AI-powered technology in building scalable, high-performance healthcare solutions. Discover how collaboration drives innovation and advances precision medicine.
Harnessing AI & Big Data: The Next Frontier in Biotech and Healthcare
Moderator:
Panelists:
We are thrilled to announce our presence at the 3rd edition of Artificial Intelligence for Oncology. You will have the chance to meet our BioPharma and Multimodal R&D experts and learn how we help BioPharma companies address challenges throughout the drug development continuum with data solutions tailored to their needs, bringing more effective drugs to the right patients.
If you are attending, don’t miss our talk on Friday, May 9th at 3.25pm, during the Industry Symposium.
“Accelerating Precision Oncology with Multimodal Data Analytics”
Hamza Boulaala, Data Scientist, Multimodal R&D, SOPHiA GENETICS
Join us in this session to learn how SOPHiA DDM™ for Multimodal is transforming the future of oncology, one breakthrough at a time:
We are excited to be at the 24th Annual Bio-IT World Conference & Expo. Join us at booth #724 and meet our BioPharma and Multimodal R&D experts to learn how we help BioPharma companies address challenges throughout the drug development continuum with data solutions tailored to their needs, bringing more effective drugs to the right patients.
If you are attending, don’t miss our talk on Friday, April 4th from 12.10 to 12.40pm, in the AI for Oncology, Precision Medicine & Health track.
“SOPHiA DDM™ for Multimodal: Advancing Precision Oncology with AI-Driven Analytics”
Paul Bernard, Data Engineer, Multimodal R&D, SOPHiA GENETICS
Join this session to explore how SOPHiA DDM™ for Multimodal is shaping the future of cancer care, one breakthrough at a time:
We are thrilled to be back at 15th World Clinical Biomarkers & Companion Diagnostics Summit Europe. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
If you are around, don’t miss our plenary talk on Wednesday, April 9th from 11.30am to 12.00pm.
New and Innovative Ways to Democratize Precision Medicine Testing
Jess Lambe, Vice President and Managing Director of BioPharma Business Development, SOPHiA GENETICS
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.